From Medscape Oncology

Coverage from the

San Antonio Breast Cancer Symposium (SABCS) 2022

December 06 - 10, 2022; San Antonio, Texas and Virtual/Online

December 06 - 10, 2022 San Antonio, Texas and Virtual/Online

SABCS 2022 CTC-guided Therapy Beats Physician Choice in Met Breast Cancer Better survival was seen when treatment choice between chemotherapy and endocrine therapy in women with HR+/HER2- metastatic breast cancer was guided by circulating tumor cell (CTC) counts.
Medscape Medical News, December 13, 2022
SABCS 2022 Worse Breast Cancer Outcomes for Black Women Tempered by BMI New data show that Black women with node positive HR+/HER2- breast cancer have worse outcomes than their white counterparts, although the difference was no longer significant after adjustment for BMI.
Medscape Medical News, December 8, 2022

Conference News

SABCS 2022 Diagnostic vs Screening Mammograms: Survey Shows Confusion
MDedge News, February 9, 2023
SABCS 2022 HER2 Low Breast Cancer: New Clinical Entity or Testing Artifact?
Medscape Medical News, January 5, 2023
SABCS 2022 Six Obstacles in Breast Cancer Detection and Treatment
Medscape Medical News, December 27, 2022
SABCS 2022 Who Benefits From 5 Years of Extended Endocrine Therapy?
Medscape Medical News, December 22, 2022
SABCS 2022 New Oral SERD Elacestrant -- for Which Breast Cancer Patients?
Medscape Medical News, December 14, 2022
SABCS 2022 T-DXd: 'Remarkable' Survival Gains in Advanced Breast Cancer
Medscape Medical News, December 14, 2022
SABCS 2022 Chemotherapy Meets Its Match Against Aggressive ER+/HER2– BRCAs
MDedge News, December 13, 2022
SABCS 2022 CTC-guided Therapy Beats Physician Choice in Met Breast Cancer
Medscape Medical News, December 13, 2022
SABCS 2022 Oral SERD Camizestrant Prolongs PFS vs Fulvestrant in Breast Cancer
MDedge News, December 13, 2022

SABCS 2022 High Response Rates With T-DXd in Early HER2-Low Breast Cancer
MDedge News, December 13, 2022
SABCS 2022 Key Research on TNBC: Top 5 Picks From SABCS
Medscape Medical News, December 13, 2022
SABCS 2022 Marker May Explain Poor Outcomes in Black Breast Cancer Patients
MDedge News, December 12, 2022
SABCS 2022 Women Can Safely Interrupt Endocrine Tx to Pursue Pregnancy
Medscape Medical News, December 12, 2022
SABCS 2022 Exciting Advances in HR+ Breast Cancer: Top 5 Picks From SABCS
Medscape Medical News, December 12, 2022
SABCS 2022 Breast Conservation Safe Option in Multisite Breast Cancer
Medscape Medical News, December 12, 2022
SABCS 2022 Test Predicts Which BC Patients Benefit From Ovarian Suppression
Medscape Medical News, December 8, 2022
SABCS 2022 Worse Breast Cancer Outcomes for Black Women Tempered by BMI
Medscape Medical News, December 8, 2022

Medscape Oncology© WebMD, LLC

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Perspectives

Want to Thank Trial Participants? Provide Crossover
Kathy D. Miller, MD
ER+ Breast Cancer Data: SERDs, Pregnancy, and New Targets
Kathy D. Miller, MD; E. Shelley Hwang, MD, MPH
Top Studies in HER2+ Breast Cancer From SABCS 2022
Ann Partridge, MD, MPH
Top Studies in Metastatic Breast Cancer From SABCS 2022
Harold J. Burstein, MD, PhD
Deescalating DCIS: Experts Discuss New Data From SABCS
Kathy D. Miller, MD; E. Shelley Hwang, MD, MPH

Popular News from SABCS 2021

Genomic Profiling Can Improve PFS in Metastatic Breast Cancer But results of genomic testing need to be interpreted carefully. An alteration-drug match not supported by clinical trial evidence has no benefit for patients.
Medscape Medical News, Dec 07, 2021
Antibiotics Link to Triple-Negative Breast Cancer Mortality? A small study suggests the frequent use of antibiotics among women with triple-negative breast cancer, may have an impact on overall and breast cancer–specific mortality.
Medscape Medical News, Dec 14, 2021
Ongoing HER2 Therapy May Cost an Additional $68,000 per Patient Meeting the treatment needs of the nearly 50% of women with metastatic breast cancer in British Columbia who could benefit from continued HER2 suppression would cost at least $68,000 more per patient.
Medscape Medical News, Dec 13, 2021

Previous Coverage

Related Resource

Breast Cancer News & Perspectives

All material on this website is protected by copyright, Copyright © 1994-2025 by WebMD LLC. This website also contains material copyrighted by 3rd parties.